Thor Medical
Logotype for Thor Medical

Thor Medical (TRMED) investor relations material

Thor Medical H1 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Thor Medical
H1 2026 earnings summary28 Aug, 2026

Executive summary

  • AlphaOne facility completed on time and on budget, now operational and delivering first patient doses, marking transition from pilot to industrial scale.

  • Initial revenues generated from pilot sales of Th-228, Ra-224, and Pb-212 isotopes, supporting growing demand for targeted alpha therapies.

  • Strategic supply agreements signed with Eckert & Ziegler and Minerva Imaging, expanding market access and strengthening the Pb-212 ecosystem.

  • Positioned as a leading supplier of high-purity radioisotopes, enabling next-generation cancer therapies with a scalable, cost-efficient production platform.

  • Lean business model avoids high capital requirements and binary risks typical of pharmaceutical development.

Financial highlights

  • H1 2026 revenue was NOK 0.9 million, up from NOK 0.1 million in H1 2025, primarily from pilot site sales.

  • EBITDA for H1 2026 was negative NOK 33.1 million, compared to negative NOK 23.1 million in H1 2025.

  • Net loss for the period was NOK 54.7 million, compared to NOK 29.7 million in H1 2025.

  • Cash and cash equivalents at period end were NOK 59.9 million, with NOK 40 million in unused credit facilities.

  • Net cash flow was negative NOK 120.1 million, reflecting AlphaOne investments and inventory build-up.

Outlook and guidance

  • Ramp-up of AlphaOne expected to drive sales to low double-digit million NOK in 2026, with NOK 350 million revenue potential after three years.

  • Production capacity expected to reach 21,000 patient doses after three years and 60,000 doses by 2035.

  • EBITDA expected to turn positive in 2027, with cash flow breakeven also targeted for 2027.

  • Market for radiopharmaceuticals, especially Pb-212, projected to grow rapidly, with significant clinical and commercial demand anticipated.

  • Revenue outlook reflects uncertainty due to early-stage production ramp-up and timing of customer deliveries.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Thor Medical earnings date

Logotype for Thor Medical
H2 202626 Feb, 2027
Thor Medical
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Thor Medical earnings date

Logotype for Thor Medical
H2 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutic products for hematological cancers in Norway. The company is developing Betalutin, an antibody radionuclide conjugate, which is in Phase III clinical trial for a range of non-Hodgkin lymphoma indications. It is also developing 177Lu-lilotomab satetraxetan (HH1), a targeted alpha immunotherapy for non-Hodgkin lymphomas. The company has strategic collaboration with NRCF to develop treatment regimens for hematological cancers and other indications using Lutathera or Betalutin; and with Servier S.A.S., as well as Cytodyn Inc.